Cerevel Therapeutics Holdings (CERE) Prices 14M Share Offering at $25/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cerevel Therapeutics Holdings (CERE) Cerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility at 143 on more puts than calls
July 2, 2021 4:42 AM EDTCerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 143; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.
... MoreCerevel Therapeutics Holdings (CERE) call put ratio 1 call to 2 puts after sharp rally
July 1, 2021 3:55 PM EDTCerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 140; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.
... MorePre-Open Stock Movers 06/30: (OCUP) (ASTS) (XELA) Higher; (ALT) (ECOR) (REPX) Lower (more...)
June 30, 2021 9:27 AM EDTPre-Open Stock Movers:
Ocuphire Pharma, Inc. (Nasdaq: OCUP) 40.6% HIGHER; announced that the VEGA-1 Phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move into Phase 3. Given the rapid onset and sustained duration of efficacy, the favorable safety profile, and the potential tunability of... More
Cerevel Therapeutics (CERE) PT Raised to $30 at Goldman Sachs
June 30, 2021 9:13 AM EDTGoldman Sachs analyst Graig Suvannavejh raised the price target on Cerevel Therapeutics (NASDAQ: CERE) to $30.00 (from $23.00) while maintaining a Buy rating.... More
